Clinical Research Directory
Browse clinical research sites, groups, and studies.
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
Sponsor: N.N. Petrov National Medical Research Center of Oncology
Summary
There is no data comparing the effectiveness of the 4 most relevant first-line therapy programs for peripheral T-cell lymphomas (CHOEP, CHOP, CHEP-BV, CHP-BV) in a single study. For the first time, the effectiveness and toxicity of various first-line PTCL therapy programs in patients with T-cell lymphoma will be analyzed in the conditions of a single medical center of the N.N.Petrov National Research Medical Center of Oncology and optimal therapeutic tactics will be determined, taking into account significant prognostic factors based on effectiveness and toxicity a specific chemotherapy regimen.
Official title: Optimization of the First-line Therapy of T-cell Lymphomas
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
114
Start Date
2013-10
Completion Date
2028-12
Last Updated
2025-12-02
Healthy Volunteers
No
Conditions
Interventions
Doxorubicin
doxorubicin 50 mg/m2, day 1
Vincristine
vincristine 1.4 mg/m2, (maximum dose 2 mg) day 1
Etoposide
Etoposide 100 mg/m2, 1-3 days
cyclophosphamide
cyclophosphamide 750 mg/m2, day 1
Prednisone
prednisone 100 mg, 1-5 days
Brentuximab Vedotin (Bv)
brentuximab vedotin 1.8 mg / kg, day 1